Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Status:
Completed
Trial end date:
2017-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible
PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF
(NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients
with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified
interim analysis in March 2014.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Angiotensin Receptor Antagonists LCZ 696 Sacubitril and valsartan sodium hydrate drug combination